BioDuro and Atombeat partner to accelerate AI-powered peptide drug discovery
Ella Day | July 31, 2025 | News story | Mergers and Acquisitions | AI, BioDuro, Corporate, Devices
BioDuro and Atombeat have announced a partnership to launch an artificial intelligence (AI)-driven platform designed to accelerate peptide drug discovery from molecular design to preclinical candidates. The collaboration combines BioDuro’s deep expertise in peptide chemistry, biology and drug metabolism and pharmacokinetics with Atombeat’s AI modelling technologies for faster, more cost-effective development of peptide therapeutics.
Specifically, Atombeat’s Hermite and RiDYMO software suite, which enables in-silico exploration of over one trillion peptide compounds, is built from a collection of more than 1,000 natural and non-natural amino acids. These tools combine AI, reinforced dynamics and predictive modelling to efficiently screen candidates based on key traits like membrane permeability – before any lab testing begins.
Once candidates are identified, BioDuro uses its high-throughput synthesis technology to produce hundreds of high-purity peptides within a week, bypassing traditional purification steps. This integration with in-house biology assays enables rapid validation, significantly reducing R&D timelines and costs.
“We are excited to advance peptide innovation through our strategic partnership with Atombeat,” said Armin Spura, CEO of BioDuro. “Together, we aim to deliver smarter, more efficient drug development solutions.”
Dongdong Wang, co-founder of Atombeat, added: “This partnership reflects our commitment to combining AI and experimentation to meet global clinical needs.”
Ella Day
31/7/25
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
MultiOmic Health and BIO4 Campus sign collaborative Memorandum of Understanding
MultiOmic Health (MOH), an artificial intelligence (AI)-enabled precision medicine biotechnology company and BIO4 Campus (BIO4), …
Sanome’s AI tool gains certification for early detection of hospital infections
Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to …
